Retatrutide Shows 24.2% Weight Reduction in Phase II Trial

The management of obesity is complex, with a significant proportion of patients failing to achieve sustainable weight loss through diet and exercise alone. Pharmacological interventions have evolved, with glucagon-like peptide-1 (GLP-1) receptor agonists demonstrating efficacy in weight reduction and improvement in metabolic parameters. Newer agents, such as dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have further enhanced these effects. Retatrutide represents a novel investigational therapy, designed as a triple agonist for the GIP, GLP-1, and glucagon receptors, aiming to leverage the synergistic effects of these pathways for enhanced metabolic benefits.¹

The Trial Design and Key Findings

A Phase II, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of retatrutide in adults with obesity or overweight with at least one weight-related comorbidity, excluding type 2 diabetes.¹ The trial enrolled 338 participants, who were randomly assigned to receive either placebo or one of several doses of retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) administered subcutaneously once weekly for 48 weeks.¹

The primary endpoint was the percentage change in body weight from baseline to week 24. Secondary endpoints included the percentage change in body weight from baseline to week 48, the proportion of participants achieving specific weight loss thresholds (e.g., ≥5%, ≥10%, ≥15%), and changes in cardiometabolic risk factors.¹

At week 24, participants receiving retatrutide showed dose-dependent reductions in body weight. The mean percentage change in body weight from baseline was -8.7% with 1 mg, -17.1% with 4 mg, -17.5% with 8 mg, and -14.6% with 12 mg, compared to -2.0% with placebo (p<0.001 for all active doses versus placebo).¹

By week 48, the weight loss continued to increase. The mean percentage change in body weight from baseline was -8.7% with 1 mg, -21.2% with 4 mg, -22.8% with 8 mg, and -24.2% with 12 mg, compared to -2.1% with placebo (p<0.001 for all active doses versus placebo).¹ Notably, 100% of participants in the 8 mg and 12 mg retatrutide groups achieved at least 5% weight loss, compared to 27% in the placebo group.¹ Furthermore, 83% of participants in the 12 mg group achieved at least 20% weight loss, a threshold often associated with significant health benefits.¹

Beyond weight reduction, retatrutide also demonstrated improvements in several cardiometabolic parameters. Significant reductions were observed in fasting glucose, insulin, HbA1c, lipid levels (total cholesterol, LDL-C, triglycerides), and blood pressure in the retatrutide groups compared to placebo.¹ Liver fat content, assessed by magnetic resonance imaging, also showed substantial reductions, with a mean decrease of 81.8% in the 12 mg group, suggesting potential benefits for non-alcoholic fatty liver disease.¹

The safety profile was consistent with other incretin-based therapies. The most common adverse events were gastrointestinal, including nausea, diarrhoea, vomiting, and constipation, generally mild to moderate in severity and transient.¹ Discontinuation rates due to adverse events were 16% in the 12 mg group and lower in other active treatment groups, compared to 5% in the placebo group.¹

While these Phase II results are compelling, the trial duration of 48 weeks limits the assessment of long-term efficacy and safety. The relatively small sample size for each dose group also warrants caution, and larger Phase III trials are necessary to confirm these findings across broader and more diverse patient populations. The exclusion of individuals with type 2 diabetes means the full spectrum of metabolic benefits and risks in this specific cohort remains to be fully elucidated. Further research is also needed to understand the precise mechanisms contributing to the observed triple-agonist effects and their differential impact compared to dual agonists.